NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

BIO

Bio-Rad Laboratories Inc. Class A New York Stock Exchange
$591.94
Open: $592.08 High: $605.1 Low: $584.01 Close: $591.39
Range: 2021-02-24 - 2021-02-25
Volume: 245,819
Market: Open
Powered by Finage Stock APIDelayed data
BIO
Bio-Rad Laboratories Inc. Class A 1000 Alfred Nobel Drive Hercules CA, 94547 http://www.bio-rad.com
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.
  • CEO: Norman Schwartz
  • Employees: 8,150
  • Sector: Healthcare
  • Industry: Medical Diagnostics & Research
BIO News
Latest news about the BIO
  • Top Healthcare Stocks for March 2021

    These are the healthcare stocks with the best value, fastest growth, and most momentum for March 2021.

    View More →
  • Top Stocks for March 2021

    The Russell 1000 Index is a market-capitalization-weighted index of the 1000 largest publicly traded companies in the U.S. It represents approximately 92% of the total market capitalization of all listed stocks in the U.S. equity market. Value investing is a factor-based investing strategy in which you pick stocks that you believe are trading for less than what they are intrinsically worth, usually by measuring the ratio of the stock's price to one or more fundamental business metrics. A widely accepted value metric is the price-to-earnings ratio (P/E Ratio).

    View More →
  • Bio-Rad to Participate in Citi’s 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Wednesday, February 24, at 11:25 AM (PST).

    View More →
  • Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

    Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

    View More →
  • Bio-Rad Laboratories Inc (BIO) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Q4 and Full Year 2020 Bio-Rad Laboratories Inc. Earnings Conference Call. Today, we will review the fourth quarter and full year results of 2020. With me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Annette Tumolo, President of the Life Science group; and Dara Wright, President of the Clinical Diagnostics group.

    View More →
  • Bio-Rad 4Q Sales Top Estimates Driven By COVID-19 Demand

    Bio-Rad Laboratories outperformed fourth-quarter earnings and sales estimates as the life science research and clinical diagnostic company benefited from strong demand for its COVID-19 products during the pandemic. Shares rose 2% in Thursday’s post-market trading session. During the fourth quarter, Bio-Rad’s (BIO) revenue increased 26.5% year-on-year to $789.8 million, topping analysts’ expectations of $686.8 million. The company reported diluted earnings per share (EPS) of $4.01, beating the Street consensus of $3.29. Gross margin improved from 52.9% to 58.3% during the reported period. Higher demand for Bio-Rad’s PCR product lines due to the COVID-19 pandemic led to a 73.9% year-on-year sales increase in the company’s life science segment to $428.5 million in 4Q. Meanwhile, sales at the company’s clinical diagnostics segment dropped 6.6% to $359.6 million. Notably, the US Food and Drug Administration (FDA) on Feb. 11 granted emergency use authorization for Bio-Rad’s COVID-19, influenza A and influenza B RT-PCR test, which can discriminate between the three viruses. Bio-Rad CEO Norman Schwartz said while many of the company’s markets are yet functioning at less than 100%, the demand for COVID-19 products exceeded expectations in 4Q and strict cost control led to improvement in operating profit for 2020. For fiscal 2020, Bio-Rad’s revenue increased to $2.55 billion from $2.31 billion year-on-year. Earnings jumped from $7.06 to $10.52 per share during the same comparative period. Looking ahead to fiscal 2021, Bio-Rad forecasted currency neutral revenue growth of 4.5% to 5%. The company expects operating margin to be in the range of 16% to 16.5% (See Bio-Rad stock analysis on TipRanks) On Feb. 5, Jefferies analyst Brandon Couillard raised the stock’s price target from $660 to $725 (13% upside potential) and reiterated Buy rating. Brandon noted that the market seemed to have overlooked the ~25% jump in Sartorius stock in the past year which adds $2 billion to Bio-Rad’s stake in the company. He sees a compelling safety margin in the stock at the current level. Related News: J&J Files For FDA Approval Of COVID-19 Vaccine; Street is Bullish Baidu In Talks To Raise Funds For Semiconductor Company – Report Microsoft Showed Interest In Pinterest Takeover – Report More recent articles from Smarter Analyst: Limelight Sinks 18% As Quarterly Sales Disappoint Amid Pricing Pressure Disney Surprises With Quarterly Profit Amid Streaming Subscriber Boom Regeneron Wins FDA Nod For Evkeeza Antibody Therapy; Street Sees 34% Upside HubSpot Pops 16% After-Market On Blowout Quarterly Profit

    View More →
  • Bio-Rad Laboratories (BIO) Q4 Earnings and Revenues Surpass Estimates

    Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Bio-Rad Laboratories: Q4 Earnings Insights

    Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over year to $4.01, which beat the estimate of $3.29. Revenue of $789,839,000 up by 26.49% from the same period last year, which beat the estimate of $686,800,000. Looking Ahead Bio-Rad Sees FY21 Adj. Currency-Neutral Sales Growth 4.5-5% Year Over Year Details Of The Call Date: Feb 11, 2021 Time: 06:00 PM View more earnings on BIO ET Webcast URL: https://edge.media-server.com/mmc/p/8cfv55c7 Technicals 52-week high: $648.39 Company's 52-week low was at $309.38 Price action over last quarter: Up 9.79% Company Overview Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 11, 2021Earnings Preview: Bio-Rad Laboratories© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter ended December 31, 2020.

    View More →
  • Earnings Preview: Bio-Rad Laboratories

    Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings. Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Bio-Rad Laboratories EPS is expected to be around $3.29, according to sell-side analysts. Sales will likely be near $686.80 million. Bio-Rad Laboratories earnings in the same period a year ago was $2.32 per share. Quarterly sales came in at $624.43 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin. View more earnings on BIO If the company were to post earnings in line with the consensus estimate when it reports Thursday, EPS would be up 41.81%. Revenue would be up 9.99% from the year-ago period. Bio-Rad Laboratories's reported EPS has stacked up against analyst estimates in the past like this: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate 1.8 1.15 1.61 2.44 EPS Actual 3 1.61 1.91 2.32 Revenue Estimate 570.58 M 503.82 M 554.89 M 641.95 M Revenue Actual 647.26 M 536.88 M 571.64 M 624.43 M Stock Performance Shares of Bio-Rad Laboratories were trading at $636.46 as of February 09. Over the last 52-week period, shares are up 69.52%. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Bio-Rad Laboratories is scheduled to hold the call at 18:00:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaA Look Into Healthcare Sector Value Stocks© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Medical Products' Feb 11 Earnings Roster: DXCM, LH & More

    The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

    View More →
  • A Look Into Healthcare Sector Value Stocks

    What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: XBiotech (NASDAQ:XBIT) - P/E: 1.37 Voyager Therapeutics (NASDAQ:VYGR) - P/E: 7.03 Bio-Rad Laboratories (NYSE:BIO) - P/E: 5.28 Jaguar Health (NASDAQ:JAGX) - P/E: 0.82 Exagen (NASDAQ:XGN) - P/E: 0.47 XBiotech saw an increase in earnings per share from -0.24 in Q2 to -0.09 now. XBiotech does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Voyager Therapeutics saw an increase in earnings per share from -0.23 in Q2 to 2.27 now. Voyager Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Bio-Rad Laboratories saw an increase in earnings per share from 1.61 in Q2 to 3.0 now. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Jaguar Health has reported Q3 earnings per share at -0.21, which has increased by 52.27% compared to Q2, which was -0.44. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. This quarter, Exagen experienced a decrease in earnings per share, which was -0.27 in Q2 and is now -0.34. Exagen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize. See more from BenzingaClick here for options trades from BenzingaA Look Into Real Estate Sector Value StocksRecap: General Finance Q2 Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

    Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

    View More →
  • 10 Cheap Healthcare Stocks To Buy Now

    In this article we discuss 10 cheap healthcare stocks to buy now. You can skip our detailed analysis of the healthcare industry, growth catalysts for healthcare stocks and go directly to 5 Cheap Healthcare Stocks To Buy Now. Healthcare remains one of the most evergreen areas for investment. The S&P 500 Health Care Sector Index […]

    View More →
  • Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2020 on Thursday, February 11, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.

    View More →
  • Bio-Rad's CEO Just Shared His Four-Part Plan For Success

    Norman Schwartz got an up-close view of biological science and what it took to be a Bio-Rad CEO at an early age.

    View More →
  • A Trio of High Earnings Return Stocks

    They are thrashing the 20-year high-quality market corporate bonds

    View More →
  • Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at 1:30 PM (PST).

    View More →
  • Bio Rad Labs Sees Composite Rating Improve To 96

    Bio Rad Labs saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before. The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. Bio Rad Labs is currently forming a cup without handle, with a 648.49 entry.

    View More →
  • Is BIO A Good Stock To Buy Now?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    View More →